Rallybio Corp

For the period ended Mar 31, 2024. Filed May 9, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 9, 2024

RLYB$15.76+0.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Condensed Consolidated Statements of Cash Flows

Condensed Consolidated Statements of Cash Flows

	FOR THE THREE MONTHS ENDED MARCH 31,
(in thousands)	2024	2023
Cash Flows Used in Operating Activities:
Net loss	$(19,029)	$(17,318)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	35	39
Net accretion of discounts/premiums on debt securities	(539)	(895)
Stock-based compensation	2,088	3,045
Loss on investment in joint venture	685	563
Changes in operating assets and liabilities:
Prepaid expenses, right-of-use assets and other assets	537	(340)
Accounts payable	(506)	(295)
Accrued expenses and operating lease liabilities	1,272	(3,564)
Net cash used in operating activities	(15,457)	(18,765)
Cash Flows Provided By Investing Activities:
Purchases of marketable securities	(10,736)	(29,285)
Proceeds from maturities of marketable securities	21,750	31,500
Investment in joint venture	(750)	(750)
Net cash provided by investing activities	10,264	1,465
Cash Flows Used In Financing Activities:
Payments of offering costs	—	(139)
Net cash used in financing activities	—	(139)
Net decrease in cash and cash equivalents	(5,193)	(17,439)
Cash and cash equivalents —beginning of period	24,494	56,958
Cash and cash equivalents —end of period	$19,301	$39,519

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.